Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 409

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 409
---
) | Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to warrants, options and other convertible securities held by that person that are currently exercisable or exercisable within 60 days of March 31, 2025 are deemed outstanding. Shares subject to warrants, options and other convertible securities, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other person. |

| (2) | Consists of 350,000 shares of Common Stock held directly and 382,717 shares underlying certain warrants to purchase Common Stock, with an exercise price of $0.01 per share, held by the Selling Stockholder exercisable within 60 days of March 31, 2025. Such warrants held by the Selling Stockholder are subject to a 9.99% beneficial ownership limitation and the number of shares of Common Stock set forth in the table above give effect to such limitation. The foregoing ownership information for the Selling Stockholder is based on information supplied by the Selling Stockholder in a statement on Schedule 13G filed with the SEC on January 17, 2025 that reports its sole voting power and sole dispositive power and a Form 4 filed with the SEC by SCLX JV on January 23, 2025. The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue of the Americas, Third Floor, New York, NY 10036. |

| (3) | Comprised of 6,500,000 shares issuable upon the exercise of the Penny Warrants and 185,714 shares previously issued upon the exercise of the Penny Warrants. |

| (4) | Consists of 164,285 shares of Common Stock held directly and 533,578 shares underlying certain warrants to purchase Common Stock and certain convertible notes to purchase Common Stock, held by the Selling Stockholder exercisable within 60 days of March 31, 2025. Such warrants and convertible notes held by the Selling Stockholder are subject to a 4.99% beneficial ownership limitation and the number of shares of Common Stock set forth in the table above give effect to such limitation. |

258

PLAN OF DISTRIBUTION The Selling Stockholder of the securities and any of its pledgees, donees, transferees, distributees, assignees and successors-in-interestmay, from time to